BR9407693A - Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto - Google Patents

Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto

Info

Publication number
BR9407693A
BR9407693A BR9407693A BR9407693A BR9407693A BR 9407693 A BR9407693 A BR 9407693A BR 9407693 A BR9407693 A BR 9407693A BR 9407693 A BR9407693 A BR 9407693A BR 9407693 A BR9407693 A BR 9407693A
Authority
BR
Brazil
Prior art keywords
vector
nucleotide sequence
compound
pharmaceutical composition
composition use
Prior art date
Application number
BR9407693A
Other languages
English (en)
Inventor
Fabien Schweighoffer
Bruno Tocque
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of BR9407693A publication Critical patent/BR9407693A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
BR9407693A 1993-09-15 1994-05-09 Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto BR9407693A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9310971A FR2710074B1 (fr) 1993-09-15 1993-09-15 Gène GRB3-3, ses variants et leurs utilisations.
PCT/FR1994/000542 WO1995007981A1 (fr) 1993-09-15 1994-05-09 Gene grb3-3, ses variants et leurs utilisations

Publications (1)

Publication Number Publication Date
BR9407693A true BR9407693A (pt) 1997-02-04

Family

ID=9450882

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9407693A BR9407693A (pt) 1993-09-15 1994-05-09 Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto

Country Status (27)

Country Link
US (2) USRE37952E1 (pt)
EP (1) EP0719328B1 (pt)
JP (1) JP3794697B2 (pt)
KR (1) KR100330477B1 (pt)
CN (1) CN1098930C (pt)
AT (1) ATE196926T1 (pt)
AU (1) AU698819B2 (pt)
BR (1) BR9407693A (pt)
CA (1) CA2169938A1 (pt)
CZ (1) CZ288882B6 (pt)
DE (1) DE69426121T2 (pt)
DK (1) DK0719328T3 (pt)
ES (1) ES2152313T3 (pt)
FI (1) FI120499B (pt)
FR (1) FR2710074B1 (pt)
GR (1) GR3034600T3 (pt)
HU (1) HU221516B (pt)
IL (2) IL126756A (pt)
NO (1) NO319144B1 (pt)
NZ (1) NZ266162A (pt)
PL (1) PL178402B1 (pt)
PT (1) PT719328E (pt)
RU (1) RU2159815C2 (pt)
SK (1) SK281123B6 (pt)
UA (1) UA46715C2 (pt)
WO (1) WO1995007981A1 (pt)
ZA (1) ZA947059B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US6171800B1 (en) 1995-06-07 2001-01-09 Biogen, Inc. Method of making and binding CAIP polypeptides
US5837844A (en) * 1995-06-07 1998-11-17 Biogen, Inc. CAIP-like gene family
US6423824B1 (en) 1995-06-07 2002-07-23 Biogen, Inc. CAIP-like gene family
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
WO1997049808A1 (en) * 1996-06-27 1997-12-31 Biogen, Inc. The caip-like gene family
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP0998945A1 (en) * 1998-09-30 2000-05-10 Transgene S.A. Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
NZ553687A (en) 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
EP1873259B1 (en) 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
WO2003061386A1 (en) * 2002-01-03 2003-07-31 Board Of Regents, The University Of Texas System Wt1 antisense oligos for the inhibition of breast cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667803B2 (en) * 1991-01-18 1996-04-18 New York University A receptor tyrosine kinase target protein cDNA cloning method and hGRB proteins
AU5136093A (en) * 1992-09-25 1994-04-26 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof

Also Published As

Publication number Publication date
PL178402B1 (pl) 2000-04-28
EP0719328B1 (fr) 2000-10-11
ES2152313T3 (es) 2001-02-01
ZA947059B (en) 1995-05-18
JP3794697B2 (ja) 2006-07-05
PL313445A1 (en) 1996-07-08
CN1098930C (zh) 2003-01-15
CZ75896A3 (en) 1996-06-12
IL126756A (en) 2006-06-11
AU698819B2 (en) 1998-11-05
RU2159815C2 (ru) 2000-11-27
DK0719328T3 (da) 2000-11-13
CA2169938A1 (fr) 1995-03-23
USRE37952E1 (en) 2002-12-31
FR2710074B1 (fr) 1995-12-08
HU221516B (hu) 2002-11-28
NO960965D0 (no) 1996-03-08
IL110942A0 (en) 1994-11-28
FI961202A (fi) 1996-03-14
JPH09502357A (ja) 1997-03-11
KR100330477B1 (ko) 2002-12-02
FR2710074A1 (fr) 1995-03-24
FI120499B (fi) 2009-11-13
PT719328E (pt) 2001-02-28
DE69426121T2 (de) 2001-05-31
NO319144B1 (no) 2005-06-27
WO1995007981A1 (fr) 1995-03-23
CZ288882B6 (cs) 2001-09-12
HU9600668D0 (en) 1996-05-28
ATE196926T1 (de) 2000-10-15
NZ266162A (en) 1997-11-24
SK281123B6 (sk) 2000-12-11
EP0719328A1 (fr) 1996-07-03
SK34596A3 (en) 1996-07-03
CN1133064A (zh) 1996-10-09
UA46715C2 (uk) 2002-06-17
FI961202A0 (fi) 1996-03-14
GR3034600T3 (en) 2001-01-31
DE69426121D1 (de) 2000-11-16
IL110942A (en) 2001-12-23
US5831048A (en) 1998-11-03
NO960965L (no) 1996-03-08
AU6724794A (en) 1995-04-03
HUT74273A (en) 1996-11-28

Similar Documents

Publication Publication Date Title
BR9407693A (pt) Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
HUP0204199A2 (hu) Transzport vektorok
CO5590973A2 (es) Acido nucleico de adenovirus de simio y secuiencias de aminoacidos, vectores que contienen los mismos y metodos de uso
DE69232537D1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
DK0750506T3 (da) Bredspektrede, antimikrobielle forbindelser og fremgangsmåder til anvendelse af disse
IT1242149B (it) Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
GR3024597T3 (en) 7-deazapurine modified oligonucleotides
FI962247A (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
BR0312889A (pt) Polipeptìdeo t20 peguilado
DK0811071T3 (da) Amplifikeringssekvenser hidrørende fra desmin-genet, vektorer indeholdende disse sekvenser og anvendelse heraf til fremstilling af proteiner
PT789764E (pt) Nova familia de inibidores de protease e outras substancias biologicas activas
DK1127064T3 (da) Hidtil ukendte aminosyresekvenser, DNA, der koder for aminosyresekvenserme, antistoffer, der er rettet mod sådanne sekvenser, og forskellige anvendelser deraf
DE69526087D1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
NO981707L (no) Xylanase, oligonukleotidsekvens som koder for xylanase og anvendelse derav
GB9604518D0 (en) Novel compounds
NZ509284A (en) Tumour antigen peptide derived from SART-that binds to HLA-A24 antigen thereby facilitating recognition by a T call
MY134618A (en) Filarial parasite polypeptides and sequences, gene sequences and uses thereof
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal